Rendering

Component: (Network and Table)
Network
100330 - Disclosure - Stock-based Compensation (Tables)
(http://www.alderbio.com/20161231/taxonomy/role/DisclosureStockBasedCompensationTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
 
Summary of Activity under ESPP

Activity under the ESPP for the years ended December 31, was as follows:

 

 

 

 

 

Number of shares purchased

 

Purchase price

 

 

2016

 

 

2015

 

 

2014

 

$

8.50

 

 

 

63,291

 

 

 

89,440

 

 

 

32,101

 

$

13.87

 

 

 

2,865

 

 

 

2,540

 

 

 

 

$

20.02

 

 

 

30,389

 

 

 

 

 

 

 

$

25.56

 

 

 

5,158

 

 

 

 

 

 

 

$

36.14

 

 

 

 

 

 

1,253

 

 

 

 

 

 

 

 

 

101,703

 

 

 

93,233

 

 

 

32,101

 

 

 
 
Weighted Average Assumptions used to Determine Fair Value of Stock Awards

In determining the fair value of stock awards granted, the following weighted average assumptions were used in the Black-Scholes option pricing model for awards granted in the periods indicated:

 

 

 

Stock Options

 

 

Employee Stock Purchase Plan

 

 

 

 

Years Ended

 

 

Year Ended

 

 

 

 

December 31,

 

 

December 31,

 

 

 

 

2016

 

 

2015

 

 

2014

 

 

2016

 

 

2015

 

 

2014

 

 

Volatility

 

 

60.5%

 

 

 

59.5%

 

 

 

66.1%

 

 

 

68.0%

 

 

 

57.0%

 

 

 

59.1%

 

 

Expected term (years)

 

 

6.1

 

 

 

6.1

 

 

 

6.1

 

 

 

1.4

 

 

 

0.9

 

 

 

0.6

 

 

Risk-free interest rate

 

 

1.4%

 

 

 

1.6%

 

 

 

1.9%

 

 

 

0.8%

 

 

 

0.3%

 

 

 

0.1%

 

 

Dividend rate

 

 

0.0%

 

 

 

0.0%

 

 

 

0.0%

 

 

 

0.0%

 

 

 

0.0%

 

 

 

0.0%

 

 

 

 
 
Stock Based Compensation Expense

 

The following table presents stock-based compensation expense included in the Company’s consolidated statements of operations:

 

 

 

Years Ended

 

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

2014

 

 

 

(in thousands)

 

Research and development

 

$

7,578

 

 

$

3,449

 

 

$

701

 

General and administrative

 

 

6,379

 

 

 

2,690

 

 

 

549

 

 

 

$

13,957

 

 

$

6,139

 

 

$

1,250

 

 

 
 
Stock Option Activity

A summary of the Company’s stock option activity and related information follows:

 

 

 

 

 

 

 

Weighted

average

 

 

Weighted

average

 

 

Aggregate

 

 

 

 

 

 

 

exercise

 

 

remaining contractual

 

 

intrinsic value

 

 

 

Shares

 

 

price per share

 

 

life (years)

 

 

(in thousands)

 

Options, Outstanding at beginning of period

 

 

2,961,107

 

 

$

14.29

 

 

 

6.7

 

 

$

57,281

 

Granted

 

 

2,362,075

 

 

 

25.95

 

 

 

 

 

 

 

 

 

Exercised

 

 

(376,919

)

 

 

2.44

 

 

 

 

 

 

 

 

 

Forfeited and expired

 

 

(28,211

)

 

 

28.44

 

 

 

 

 

 

 

 

 

Options, Outstanding at end of period

 

 

4,918,052

 

 

$

20.72

 

 

 

7.8

 

 

$

23,098

 

Exercisable at December 31, 2016

 

 

1,800,362

 

 

$

11.43

 

 

 

5.6

 

 

$

21,310

 

Vested and expected to vest at December 31, 2016

 

 

4,843,599

 

 

$

20.62

 

 

 

7.8

 

 

$

23,087

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
Summary of Stock Option Value

The following table summarizes the Company’s stock option values:

 

 

 

Years Ended

 

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

2014

 

 

 

(in thousands, except per share data)

 

Weighted average fair value of option shares granted

   during the period

 

$

14.63

 

 

$

17.43

 

 

$

7.25

 

Total intrinsic value of stock options exercised

 

 

10,179

 

 

 

20,389

 

 

 

2,590

 

Total fair value of stock options vested

 

 

9,207

 

 

 

2,133

 

 

 

683